CAI · Caris Life Sciences, Inc.
$32.46
+1.42% last session
End-of-day data · close of 2026-10-26
Market cap
$9B
Enterprise value
$9B
Trailing P/E
19.2
Forward P/E
87.3
Dividend yield
0.0%
Beta
—
Avg volume
5M
Employees
2K
Daily Change %
1.42%
5 Days Change
2.35%
10 Days Change
6.20%
30 Days Change
1.49%
60 Days Change
26.63%
Month to Day Change
14.48%
Year to Day Change
20.29%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CAI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
JP Morgan
Overweight$35.00
+7.8% vs priceUBS
Neutral$28.00
-13.7% vs priceCitigroup
Buy$28.00
-13.7% vs priceJefferies
Buy$28.00
-13.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Maintains | Hold | $22.00 → $30.00 |
| 2026-10-14 | JP Morgan | Maintains | Overweight | $25.00 → $35.00 |
| 2026-10-13 | TD Cowen | Maintains | Buy | $30.00 → $36.00 |
| 2026-09-09 | UBS | Initiates | Neutral | $0.00 → $28.00 |
| 2026-08-06 | Evercore ISI Group | Maintains | Outperform | $25.00 → $26.00 |
| 2026-08-06 | BTIG | Maintains | Buy | $32.00 → $33.00 |
| 2026-08-05 | JP Morgan | Maintains | Overweight | $30.00 → $25.00 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $30.00 → $25.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 15.2% above the 50-day MA ($28.17).
- bullish: Price vs 200-day MA: Trading 51.6% above the 200-day MA ($21.41).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.09) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($32.46).
CAI Price Chart
Loading chart for CAI…
Fundamentals
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.